Off-label use of bedaquiline in children and adolescents with multidrug-resistant TB
Abstract
We describe 27 children
and adolescents <18 years of age who received bedaquiline
during treatment for multidrug-resistant tuberculosis. We
report good treatment responses and no cessation attributable
to adverse effects. Bedaquiline could be considered for use
with this age group for multidrug-resistant tuberculosis when
treatment options are limited.
To read the full study, click
here.
Source:
Emerging Infectious Disease
